Low estrogen plausibly makes stimulant medication work less well. A 2026 review in Drugs & Aging states that stimulants "may be more effective during high-oestrogen phases of the menstrual cycle and less effective when oestrogen is low." The same review states there are no randomized controlled trials in perimenopausal women. So the mechanism is plausible and the protocol does not exist yet.
This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication routine. Nothing here is a reason to change a dose or start hormone therapy on your own.
What the evidence actually says, and where it stops
Two sentences from the same 2026 review, and you need both.
The first is the proposed mechanism. Stimulants act on dopamine, and a 2026 European Psychiatry paper describes how "estrogen withdrawal may intensify deficits in dopaminergic and serotonergic signaling, potentially worsening attentional control, emotional regulation, and social cognition." Note the word may. This is a proposed pathway, not a measured one.
The second is the limit:
"Evidence for the efficacy and safety of stimulant and non-stimulant medications in this population is limited, with no randomised controlled trials specific to (peri)menopausal women."
No trials. Not weak trials, not mixed trials. None.
That matters for what you do next. There is no tested dose adjustment to ask for, no validated schedule, no protocol a good clinician is withholding from you. What exists is a plausible mechanism, a lot of clinical experience, and your own record.
You are probably not too young for this
The most common way this gets dismissed, including by women themselves, is on age. NICHD puts menopause usually between ages 45 and 55, with an average age of 51. If you are 38, perimenopause sounds like the wrong explanation.
A population-based cohort of 5,392 women, published in European Psychiatry in 2025, suggests otherwise. It compared 535 women with ADHD against 4,857 without, scoring perimenopausal symptoms.
| Measure | Women with ADHD | Women without ADHD |
|---|---|---|
| Total symptom score | 18.0 | 13.0 |
| Total score, ages 35 to 39 | 19.0 | 12.5 |
| Severe symptoms overall | 54.2% | 30.1% |
| Severe psychological symptoms | 58.6% | 36.0% |
| Severe somatic symptoms | 30.4% | 13.9% |
| Mean age of the group | 43.6 years | 45.7 years |
Read the second row twice. Women with ADHD aged 35 to 39 scored 19.0, higher than their own group's overall average of 18.0 and well above the 12.5 recorded for women without ADHD in that same age band. The gap on severe symptoms overall was a prevalence ratio of 1.80 (95% CI 1.64 to 1.98), and for somatic symptoms 2.20 (1.88 to 2.57).
This is an observational cohort, so it shows an association and not a cause. It does not prove your medication is working less well. It does mean "I am only 38" is a weak reason to rule the transition out.
When your ADHD medication problem is not the perimenopause
The mechanism is plausible enough to be tempting, and that is exactly why it is worth checking the plainer explanations first. Several of these are common in this age range and each is treatable on its own terms.
- Sleep. Night sweats and early waking are listed in the review alongside the cognitive symptoms, and a stimulant does not restore a night you did not get.
- Thyroid disease and iron deficiency. Both cause fatigue and poor concentration, and both are checked with a blood test rather than guessed at.
- Depression or anxiety, which the review names as part of the presentation and which change how a stimulant feels.
- A dose that was always marginal. If it was barely enough at 34, a small change in anything tips it, including when in the day you take it.
- Something mechanical, like a switch between XR and IR or a generic change, or simply a missed dose you did not register.
- A break in the routine. The same "why does this feel different now" question comes up after a summer off medication, and the answer there is usually the routine rather than the drug.
The review also notes the drug class matters. Atomoxetine has "demonstrated benefit in a small study of (peri)menopausal women without ADHD," and guanfacine and clonidine act on a different receptor system entirely. If your medication is not a stimulant, the estrogen and dopamine reasoning does not transfer to it directly.
What is actually worth doing
You cannot fix a missing trial. You can bring your prescriber something better than "it feels like it stopped working."
The review recommends "regular use of mood- and cycle-tracking applications" so that women and clinicians can "visualise fluctuations in attention, mood and medication response across hormonal phases." Cycle apps handle the hormonal half of that well.
The half they do not handle is the dose. A record of your symptoms across the month tells you nothing about medication response unless you also know, for each of those days, what time you actually took it and whether you took it at all. Those are different questions, and only one of them is about hormones.
So a useful record has three columns: the date, the time the dose was actually taken, and how the day went. Two or three months of that turns a vague complaint into something a clinician can read a pattern from.
⛔ To be clear about what not to do. Do not increase your dose, split it, move it around the cycle, or start hormone therapy because of anything here. There is no trial supporting any of those moves in this population, and stimulants are controlled medications with cardiovascular monitoring requirements. That conversation belongs to your prescriber. If hormone therapy is already on the table for you, how long HRT takes to work and the patch versus pill decision are separate questions with their own answers.
How Pillo helps
Pillo covers the dose column. It logs the time you actually take each dose, keeps the alarm going until you respond so the record is not built from memory, and keeps an adherence history you can look back across. It also has a mood tracker, so the "how the day went" column can sit next to the dose times rather than in a separate app.
Cycle tracking is in the works but has not shipped yet, so for now the hormonal half needs a separate cycle app. What matters either way is that the two halves line up on the same dates.
If forgetting is part of the picture, that is its own problem worth solving first, and it is why people lose track of ADHD medication in particular.
Frequently Asked Questions
Does perimenopause make ADHD medication less effective?
It plausibly does, though it has not been tested directly. The 2026 Drugs & Aging review states stimulants "may be more effective during high-oestrogen phases of the menstrual cycle and less effective when oestrogen is low," and names perimenopause as one of those low phases. The same review confirms no randomized controlled trials exist in perimenopausal women, so the size of the effect is unknown.
Can perimenopause start in your late thirties?
Symptoms can appear then. In a cohort of 5,392 women, those with ADHD aged 35 to 39 scored 19.0 on a perimenopausal symptom scale against 12.5 for women without ADHD in the same age band. NICHD places menopause itself usually between 45 and 55, averaging 51, so symptoms preceding it by several years is consistent with that.
Are perimenopause symptoms worse if you have ADHD?
In this cohort they were. Severe perimenopausal symptoms were reported by 54.2% of women with ADHD against 30.1% of women without, a prevalence ratio of 1.80. The gap was widest for somatic symptoms, at 30.4% versus 13.9%. This is observational data, so it shows an association rather than proving ADHD causes worse symptoms.
Should I increase my ADHD medication dose during perimenopause?
That is a decision for your prescriber, and there is no trial to point them at. The 2026 review found no randomized controlled trials of stimulant or non-stimulant ADHD medication in perimenopausal women, so no validated dose adjustment protocol exists. Bring a dated record of dose times and daily function rather than asking for a specific change.
Does hormone therapy help ADHD symptoms in perimenopause?
The 2026 review describes menopausal hormone therapy as something a clinician may consider alongside ADHD treatment for mood, sleep and cognitive symptoms, not as an ADHD treatment in itself. It is a prescribing decision that weighs your full medical history, and it is not something to start based on ADHD symptoms alone. If you are already on it, progesterone is dosed at night for a reason that has nothing to do with ADHD.
Does this apply to non-stimulant ADHD medication?
Not in the same way. The estrogen reasoning runs through dopamine, and stimulants act on dopamine. The review notes atomoxetine "has demonstrated benefit in a small study of (peri)menopausal women without ADHD," while guanfacine and clonidine work on alpha-2 receptors. The mechanism that makes the stimulant question interesting does not transfer directly to those drugs.
This article provides general information about medication management and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before making changes to your medication schedule.
